KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Other Non-Current Liabilities (2018 - 2024)

Historic Other Non-Current Liabilities for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Q4 2024 value amounting to $11.1 million.

  • Aurinia Pharmaceuticals' Other Non-Current Liabilities rose 179.64% to $11.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $11.1 million, marking a year-over-year increase of 179.64%. This contributed to the annual value of $11.1 million for FY2024, which is 179.64% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Other Non-Current Liabilities of $11.1 million as of Q4 2024, which was up 179.64% from $10.8 million recorded in Q3 2024.
  • Aurinia Pharmaceuticals' Other Non-Current Liabilities' 5-year high stood at $17.9 million during Q1 2021, with a 5-year trough of $3.4 million in Q2 2020.
  • Over the past 5 years, Aurinia Pharmaceuticals' median Other Non-Current Liabilities value was $12.3 million (recorded in 2024), while the average stood at $12.7 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 39940.9% in 2021, then crashed by 4663.36% in 2023.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Other Non-Current Liabilities stood at $3.6 million in 2020, then skyrocketed by 346.68% to $16.0 million in 2021, then fell by 23.75% to $12.2 million in 2022, then decreased by 10.57% to $10.9 million in 2023, then increased by 1.8% to $11.1 million in 2024.
  • Its Other Non-Current Liabilities was $11.1 million in Q4 2024, compared to $10.8 million in Q3 2024 and $10.9 million in Q2 2024.